このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

Cellectis 過去の業績

過去基準チェック /06

Cellectisの収益は年間平均-1.2%の割合で減少していますが、 Biotechs業界の収益は年間増加しています。収益は年間11.8% 16.9%割合で減少しています。

主要情報

-1.2%

収益成長率

4.0%

EPS成長率

Biotechs 業界の成長	30.8%
収益成長率	-16.9%
株主資本利益率	-92.0%
ネット・マージン	-646.4%
前回の決算情報	31 Mar 2024

Recent updates

We Think Some Shareholders May Hesitate To Increase Cellectis S.A.'s (EPA:ALCLS) CEO Compensation

May 26

Is Cellectis (EPA:ALCLS) Using Debt Sensibly?

May 17

These Analysts Think Cellectis S.A.'s (EPA:ALCLS) Sales Are Under Threat

Mar 08

Cellectis (EPA:ALCLS) Is In A Strong Position To Grow Its Business

Feb 16

Are Institutions Heavily Invested In Cellectis S.A.'s (EPA:ALCLS) Shares?

Jan 12

Analysts Are Betting On Cellectis S.A. (EPA:ALCLS) With A Big Upgrade This Week

Dec 08

収支内訳

Cellectis の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。

収益と収入の歴史

ENXTPA:ALCLS 収益、費用、利益 ( )USD Millions
日付	収益	収益	G+A経費	研究開発費
31 Mar 24	12	-78	17	89
31 Dec 23	9	-109	17	88
30 Sep 23	25	-72	14	84
30 Jun 23	25	-77	16	89
31 Mar 23	25	-91	16	92
31 Dec 22	26	-91	17	98
30 Sep 22	-5	-63	11	97
30 Jun 22	4	-78	16	108
31 Mar 22	14	-99	20	113
31 Dec 21	39	-86	23	118
30 Sep 21	68	-129	40	120
30 Jun 21	67	-121	41	106
31 Mar 21	59	-113	41	97
31 Dec 20	60	-37	23	77
30 Sep 20	73	-79	41	94
30 Jun 20	73	-66	41	96
31 Mar 20	71	-67	44	98
31 Dec 19	23	-102	43	92
30 Sep 19	20	-88	45	83
30 Jun 19	11	-95	45	80
31 Mar 19	17	-69	45	73
31 Dec 18	21	-79	47	77
30 Sep 18	25	-83	50	75
30 Jun 18	31	-86	50	77
31 Mar 18	31	-105	49	77
31 Dec 17	34	-99	45	79
30 Sep 17	40	-86	44	79
30 Jun 17	45	-74	42	74
31 Mar 17	57	-56	42	78
31 Dec 16	56	-67	43	78
30 Sep 16	76	-45	40	76
30 Jun 16	74	-45	38	79
31 Mar 16	65	-64	37	73
31 Dec 15	63	-23	30	58
30 Sep 15	39	-28	25	44
30 Jun 15	37	-10	21	30
31 Mar 15	33	12	17	19
31 Dec 14	32	3	16	17
30 Sep 14	28	-8	16	19
30 Jun 14	24	-21	18	22
31 Mar 14	21	-29	21	23
31 Dec 13	18	-36	24	25
30 Sep 13	15	-33	23	22

質の高い収益: ALCLSは現在利益が出ていません。

利益率の向上: ALCLSは現在利益が出ていません。

フリー・キャッシュフローと収益の比較

過去の収益成長分析

収益動向: ALCLSは利益が出ておらず、過去 5 年間で損失は年間1.2%の割合で増加しています。

成長の加速: ALCLSの過去 1 年間の収益成長を 5 年間の平均と比較することはできません。現在は利益が出ていないためです。

収益対業界: ALCLSは利益が出ていないため、過去 1 年間の収益成長をBiotechs業界 ( 3% ) と比較することは困難です。

株主資本利益率

高いROE: ALCLSは現在利益が出ていないため、自己資本利益率 ( -92.04% ) はマイナスです。

Cellectis 過去の業績

過去 基準チェック /06

主要情報

最近の業績更新

First quarter 2024 earnings released: EPS: US$0.079 (vs US$0.49 loss in 1Q 2023)

Cellectis S.A. to Report Q1, 2024 Results on May 28, 2024

Full year 2023 earnings released: US$1.92 loss per share (vs US$1.99 loss in FY 2022)

Cellectis S.A. to Report Q1, 2024 Results on May 09, 2024

Third quarter 2023 earnings released: US$0.31 loss per share (vs US$0.63 loss in 3Q 2022)

Cellectis S.A. to Report Q3, 2023 Results on Nov 06, 2023

Recent updates

Cellectis Announces the Publication of A Scientific Article in Nature Communications

New minor risk - Profitability

First quarter 2024 earnings released: EPS: US$0.079 (vs US$0.49 loss in 1Q 2023)

Cellectis S.A. to Report Q1, 2024 Results on May 28, 2024

Cellectis S.A., Annual General Meeting, Jun 28, 2024

New major risk - Shareholder dilution

Cellectis Announces Chief Financial Officer Changes

Full year 2023 earnings released: US$1.92 loss per share (vs US$1.99 loss in FY 2022)

No longer forecast to breakeven

Cellectis S.A. to Report Q1, 2024 Results on May 09, 2024

Cellectis Presents Novel TALEN® Editing Processes Enabling Highly Efficient Gene Correction and Gene Insertion in HSPCs

Cellectis S.A. Announces Board Appointments

New major risk - Shareholder dilution

New minor risk - Profitability

New major risk - Financial position

Third quarter 2023 earnings released: US$0.31 loss per share (vs US$0.63 loss in 3Q 2022)

Cellectis S.A. to Report Q3, 2023 Results on Nov 06, 2023

New major risk - Share price stability

Less than half of directors are independent

Cellectis and Imagine Institute Publish A Proof-Of-Concept Study of A Gene Surgery Candidate to Treat Activated Phosphoinositide 3-Kinase ? Syndrome Type 1 (APDS1)

Second quarter 2023 earnings released: US$0.09 loss per share (vs US$0.42 loss in 2Q 2022)

Cellectis S.A. to Report Q2, 2023 Results on Aug 03, 2023

Cibus Global, Ltd. completed the acquisition of Calyxt, Inc. (NasdaqCM:CLXT) from Cellectis S.A. (ENXTPA:ALCLS) and others in a reverse merger transaction.

Cellectis S.A., Annual General Meeting, Jun 27, 2023

Cellectis S.A. Presents Clinical Data on AMELI-01 and Preclinical Data on Multiplex Engineering for Superior Generation of CAR T- Cells at ASGCT 2023

Cellectis Publishes Article in Frontiers in Immunology Unveiling Pre-Clinical Data on A Novel Treatment Paradigm for Successful Car T Immunotherapy Against Stroma-Rich Solid Tumors

Cellectis Announces Poster Presentation on BALLI-01 at the European Hematology Association (EHA) 2023

No longer forecast to breakeven

Full year 2022 earnings released: US$1.99 loss per share (vs US$2.55 loss in FY 2021)

Now 20% undervalued after recent price drop

Cellectis S.A. has completed a Follow-on Equity Offering in the amount of $22 million.

A Look At The Intrinsic Value Of Cellectis S.A. (EPA:ALCLS)

Cellectis S.A. has completed a Follow-on Equity Offering in the amount of $22 million.

Now 35% undervalued

Cellectis S.A. announced that it has received $20 million in funding from Cytovia Therapeutics, Inc.

Cellectis S.A. announced that it has received $20 million in funding from Cytovia Therapeutics, Inc.

Cibus Global, Ltd. entered into a definitive merger agreement to acquire Calyxt, Inc. (NasdaqCM:CLXT) from Cellectis S.A. (ENXTPA:ALCLS) and others in a reverse merger transaction.

Cibus Global, Ltd. entered into a definitive merger agreement to acquire Calyxt, Inc. (NasdaqCM:CLXT) from Cellectis S.A. (ENXTPA:ALCLS) and others in a reverse merger transaction.

Now 22% undervalued

Insufficient new directors

Cellectis S.A. Announces the Resignation of Alain Godard as a Member of the Board

Cellectis Announces First Dosing of a Patient with its In-house Manufactured Product Candidate UCART22 for the treatment of r/r B-cell ALL

Cellectis S.A Announces Positive Preliminary Clinical Data for UCART22 in ALL and UCART123 in AML

Third quarter 2022 earnings released: US$0.63 loss per share (vs US$0.82 loss in 3Q 2021)

Cellectis to Showcase Clinical Data from Ameli-01 and Preclinical Data from Ucartcs1 At Ash 2022

Cellectis S.A. to Report Q3, 2022 Results on Nov 03, 2022

Cellectis Presents Data on Two TALEN®-based Gene Therapy Preclinical Programs for Patients with Sickle Cell Disease and Mucopolysaccharidosis type I at ESGCT 2022

Cellectis Appoints Mark Frattini as Chief Medical Officer

Consensus revenue estimates fall by 29%

Analyst Forecasts Just Became More Bearish On Cellectis S.A. (EPA:ALCLS)

Second quarter 2022 earnings released: US$0.42 loss per share (vs US$0.88 loss in 2Q 2021)

Cellectis S.A. Announces Executive Changes

Cellectis S.A. Announces U.S. Food and Drug Administration Clear Cellectis’ Investigational New Drug Application to Initiate A Phase 1/2A Clinical Trial of UCART20x22 for Patients

Cellectis S.A. to Report Q2, 2022 Results on Aug 04, 2022

Cellectis Announces the Appointment of Axel-Sven Malkomes & Dr. Donald A Bergstrom, M.D., Ph.D., to its Board of Directors

Cellectis S.A., Annual General Meeting, Jun 28, 2022

Cellectis Presents Research Data on A Novel Immune-Evasive Universal CAR T-Cell At ASGCT

First quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Cellectis S.A. to Report Q1, 2022 Results on May 12, 2022

Cellectis S.A. Releases Preclinical Data on Its Product Candidate UCART20x22 At the American Association for Cancer Research Annual Meeting

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Cellectis S.A. to Report Q4, 2021 Results on Mar 03, 2022

Cellectis Appoints Bing C. Wang as Member of its Executive Committee

Cellectis’ Licensed Partner, Allogene Therapeutics, Announces Removal of FDA Clinical Hold on their Clinical Trials

Is Cellectis (EPA:ALCLS) Using Too Much Debt?

Cellectis Reports Encouraging Clinical Data from BALLI-01 Study in Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia, and Preclinical Data from TALGlobin01 at the 63rd American Society of Hematology Annual Meeting

Senior Vice President of Technical Operations - Europe Leopold Bertea has left the company

Third quarter 2021 earnings released: US$0.82 loss per share (vs US$0.71 loss in 3Q 2020)

Price target decreased to €20.50

過去基準チェック /06